Reviews Rotigotine Transdermal System


No reviews yet.

Neupro Drug Description
Neupro®
(rotigotine transdermal system)
CONTINUOUS DELIVERY FOR ONCE-DAILY APPLICATION
DRUG DESCRIPTION



What are the possible side effects of rotigotine (Neupro)?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have any of these serious side effects:

extreme drowsiness, falling asleep suddenly, even after feeling alert;
nausea, sweating, feeling light-headed, fainting;
breathing problems;
severe headache, blurred vision, trouble concentrating, chest pain, numbness,...
Read All Potential Side Effects for Neupro »




Neupro® (Rotigotine Transdermal System) is a transdermal delivery system that provides rotigotine, a non-ergolinic dopamine agonist. When applied to intact skin, Neupro is designed to continuously deliver rotigotine over a 24-hour period.
The chemical name of rotigotine is (6S)-6-{propyl[2-(2-thienyl)ethyl]amino}-5,6,7,8-tetrahydro-1-naphthalenol.
The empirical formula is C19H25NOS. The molecular weight
is 315.48. The structural formula for rotigotine is:







The asterisk designates the chiral center.
Neupro is available in three strengths: 2, 4, and 6 mg/24 hours. Each transdermal system has a release surface area of 10, 20, and 30 cm2 and contains 4.5, 9, or 13.5 mg rotigotine, respectively. See Table 1. The composition of the transdermal system per area unit is identical.
Table 1 Transdermal System Size, Drug Content, and Nominal
Delivery Rate



Neupro Nominal Dose
Rotigotine Content per System
Neupro System Size


2 mg/24 hours
4.5 mg
10 cm2


4 mg/24 hours
9 mg
20 cm2


6 mg/24 hours
13.5 mg
30 cm2



System Components and Structure
Neupro is a thin, matrix-type transdermal system composed of three layers:







Backing film
Drug matrix
Protective liner

A flexible, tan-colored backing film, consisting of an aluminized polyester
film coated with a pigment-layer on the outer side. The backing provides structural
support and protection of the drug-loaded adhesive layer from the environment.
A self-adhesive drug matrix layer, consisting of the active component rotigotine
and the following inactive components: ascorbyl palmitate, povidone, silicone
adhesive, sodium metabisulfite, and dl-alpha-tocopherol.
A protective liner, consisting of a transparent fluoropolymer-coated polyester
film. This liner protects the adhesive layer during storage and is removed
just prior to application.
Last reviewed on RxList: 4/11/2008




Neupro Drug Description
Neupro®
(rotigotine transdermal system)
CONTINUOUS DELIVERY FOR ONCE-DAILY APPLICATION
DRUG DESCRIPTION



What are the possible side effects of rotigotine (Neupro)?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have any of these serious side effects:

extreme drowsiness, falling asleep suddenly, even after feeling alert;
nausea, sweating, feeling light-headed, fainting;
breathing problems;
severe headache, blurred vision, trouble concentrating, chest pain, numbness,...
Read All Potential Side Effects for Neupro »




Neupro® (Rotigotine Transdermal System) is a transdermal delivery system that provides rotigotine, a non-ergolinic dopamine agonist. When applied to intact skin, Neupro is designed to continuously deliver rotigotine over a 24-hour period.
The chemical name of rotigotine is (6S)-6-{propyl[2-(2-thienyl)ethyl]amino}-5,6,7,8-tetrahydro-1-naphthalenol.
The empirical formula is C19H25NOS. The molecular weight
is 315.48. The structural formula for rotigotine is:







The asterisk designates the chiral center.
Neupro is available in three strengths: 2, 4, and 6 mg/24 hours. Each transdermal system has a release surface area of 10, 20, and 30 cm2 and contains 4.5, 9, or 13.5 mg rotigotine, respectively. See Table 1. The composition of the transdermal system per area unit is identical.
Table 1 Transdermal System Size, Drug Content, and Nominal
Delivery Rate



Neupro Nominal Dose
Rotigotine Content per System
Neupro System Size


2 mg/24 hours
4.5 mg
10 cm2


4 mg/24 hours
9 mg
20 cm2


6 mg/24 hours
13.5 mg
30 cm2



System Components and Structure
Neupro is a thin, matrix-type transdermal system composed of three layers:







Backing film
Drug matrix
Protective liner

A flexible, tan-colored backing film, consisting of an aluminized polyester
film coated with a pigment-layer on the outer side. The backing provides structural
support and protection of the drug-loaded adhesive layer from the environment.
A self-adhesive drug matrix layer, consisting of the active component rotigotine
and the following inactive components: ascorbyl palmitate, povidone, silicone
adhesive, sodium metabisulfite, and dl-alpha-tocopherol.
A protective liner, consisting of a transparent fluoropolymer-coated polyester
film. This liner protects the adhesive layer during storage and is removed
just prior to application.
Last reviewed on RxList: 4/11/2008




Neupro Drug Description
Neupro®
(rotigotine transdermal system)
CONTINUOUS DELIVERY FOR ONCE-DAILY APPLICATION
DRUG DESCRIPTION



What are the possible side effects of rotigotine (Neupro)?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have any of these serious side effects:

extreme drowsiness, falling asleep suddenly, even after feeling alert;
nausea, sweating, feeling light-headed, fainting;
breathing problems;
severe headache, blurred vision, trouble concentrating, chest pain, numbness,...
Read All Potential Side Effects for Neupro »




Neupro® (Rotigotine Transdermal System) is a transdermal delivery system that provides rotigotine, a non-ergolinic dopamine agonist. When applied to intact skin, Neupro is designed to continuously deliver rotigotine over a 24-hour period.
The chemical name of rotigotine is (6S)-6-{propyl[2-(2-thienyl)ethyl]amino}-5,6,7,8-tetrahydro-1-naphthalenol.
The empirical formula is C19H25NOS. The molecular weight
is 315.48. The structural formula for rotigotine is:







The asterisk designates the chiral center.
Neupro is available in three strengths: 2, 4, and 6 mg/24 hours. Each transdermal system has a release surface area of 10, 20, and 30 cm2 and contains 4.5, 9, or 13.5 mg rotigotine, respectively. See Table 1. The composition of the transdermal system per area unit is identical.
Table 1 Transdermal System Size, Drug Content, and Nominal
Delivery Rate



Neupro Nominal Dose
Rotigotine Content per System
Neupro System Size


2 mg/24 hours
4.5 mg
10 cm2


4 mg/24 hours
9 mg
20 cm2


6 mg/24 hours
13.5 mg
30 cm2



System Components and Structure
Neupro is a thin, matrix-type transdermal system composed of three layers:







Backing film
Drug matrix
Protective liner

A flexible, tan-colored backing film, consisting of an aluminized polyester
film coated with a pigment-layer on the outer side. The backing provides structural
support and protection of the drug-loaded adhesive layer from the environment.
A self-adhesive drug matrix layer, consisting of the active component rotigotine
and the following inactive components: ascorbyl palmitate, povidone, silicone
adhesive, sodium metabisulfite, and dl-alpha-tocopherol.
A protective liner, consisting of a transparent fluoropolymer-coated polyester
film. This liner protects the adhesive layer during storage and is removed
just prior to application.
Last reviewed on RxList: 4/11/2008




Neupro Drug Description
Neupro®
(rotigotine transdermal system)
CONTINUOUS DELIVERY FOR ONCE-DAILY APPLICATION
DRUG DESCRIPTION



What are the possible side effects of rotigotine (Neupro)?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have any of these serious side effects:

extreme drowsiness, falling asleep suddenly, even after feeling alert;
nausea, sweating, feeling light-headed, fainting;
breathing problems;
severe headache, blurred vision, trouble concentrating, chest pain, numbness,...
Read All Potential Side Effects for Neupro »




Neupro® (Rotigotine Transdermal System) is a transdermal delivery system that provides rotigotine, a non-ergolinic dopamine agonist. When applied to intact skin, Neupro is designed to continuously deliver rotigotine over a 24-hour period.
The chemical name of rotigotine is (6S)-6-{propyl[2-(2-thienyl)ethyl]amino}-5,6,7,8-tetrahydro-1-naphthalenol.
The empirical formula is C19H25NOS. The molecular weight
is 315.48. The structural formula for rotigotine is:







The asterisk designates the chiral center.
Neupro is available in three strengths: 2, 4, and 6 mg/24 hours. Each transdermal system has a release surface area of 10, 20, and 30 cm2 and contains 4.5, 9, or 13.5 mg rotigotine, respectively. See Table 1. The composition of the transdermal system per area unit is identical.
Table 1 Transdermal System Size, Drug Content, and Nominal
Delivery Rate



Neupro Nominal Dose
Rotigotine Content per System
Neupro System Size


2 mg/24 hours
4.5 mg
10 cm2


4 mg/24 hours
9 mg
20 cm2


6 mg/24 hours
13.5 mg
30 cm2



System Components and Structure
Neupro is a thin, matrix-type transdermal system composed of three layers:







Backing film
Drug matrix
Protective liner

A flexible, tan-colored backing film, consisting of an aluminized polyester
film coated with a pigment-layer on the outer side. The backing provides structural
support and protection of the drug-loaded adhesive layer from the environment.
A self-adhesive drug matrix layer, consisting of the active component rotigotine
and the following inactive components: ascorbyl palmitate, povidone, silicone
adhesive, sodium metabisulfite, and dl-alpha-tocopherol.
A protective liner, consisting of a transparent fluoropolymer-coated polyester
film. This liner protects the adhesive layer during storage and is removed
just prior to application.
Last reviewed on RxList: 4/11/2008




Neupro Drug Description
Neupro®
(rotigotine transdermal system)
CONTINUOUS DELIVERY FOR ONCE-DAILY APPLICATION
DRUG DESCRIPTION



What are the possible side effects of rotigotine (Neupro)?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have any of these serious side effects:

extreme drowsiness, falling asleep suddenly, even after feeling alert;
nausea, sweating, feeling light-headed, fainting;
breathing problems;
severe headache, blurred vision, trouble concentrating, chest pain, numbness,...
Read All Potential Side Effects for Neupro »




Neupro® (Rotigotine Transdermal System) is a transdermal delivery system that provides rotigotine, a non-ergolinic dopamine agonist. When applied to intact skin, Neupro is designed to continuously deliver rotigotine over a 24-hour period.
The chemical name of rotigotine is (6S)-6-{propyl[2-(2-thienyl)ethyl]amino}-5,6,7,8-tetrahydro-1-naphthalenol.
The empirical formula is C19H25NOS. The molecular weight
is 315.48. The structural formula for rotigotine is:







The asterisk designates the chiral center.
Neupro is available in three strengths: 2, 4, and 6 mg/24 hours. Each transdermal system has a release surface area of 10, 20, and 30 cm2 and contains 4.5, 9, or 13.5 mg rotigotine, respectively. See Table 1. The composition of the transdermal system per area unit is identical.
Table 1 Transdermal System Size, Drug Content, and Nominal
Delivery Rate



Neupro Nominal Dose
Rotigotine Content per System
Neupro System Size


2 mg/24 hours
4.5 mg
10 cm2


4 mg/24 hours
9 mg
20 cm2


6 mg/24 hours
13.5 mg
30 cm2



System Components and Structure
Neupro is a thin, matrix-type transdermal system composed of three layers:







Backing film
Drug matrix
Protective liner

A flexible, tan-colored backing film, consisting of an aluminized polyester
film coated with a pigment-layer on the outer side. The backing provides structural
support and protection of the drug-loaded adhesive layer from the environment.
A self-adhesive drug matrix layer, consisting of the active component rotigotine
and the following inactive components: ascorbyl palmitate, povidone, silicone
adhesive, sodium metabisulfite, and dl-alpha-tocopherol.
A protective liner, consisting of a transparent fluoropolymer-coated polyester
film. This liner protects the adhesive layer during storage and is removed
just prior to application.
Last reviewed on RxList: 4/11/2008





Other reviews about Rotigotine Transdermal System on wordpress

Nursing school in nyc
  by nursestart


Rotigotine Transdermal System Shows Significant Symptom Reduction And Tolerability In Patients With Restless Legs Syndrome
  by Moderator
ツ MNT-UCB, Inc. presented results from two Phase III pivotal trials and one open-label extension trial of rotigotine transdermal system for the treatment of moderate-to-severe restless legs syndrome […]


The Foot Blog News
  by Moderator
The Foot Blog News-October 2007 Amputation in Military Trauma Surgery A recent report in The Journal of Trauma reviewsツtheツpublished historic and modern battle casualty informationツundertaken in the collections of the […]


Restless Leg Syndrome, Drug Trial Patch
  by Thixia
Improvements over 24 Months in Patients with Moderate to Severe Idiopathic Restless Legs Syndrome Treated with a Rotigotine Transdermal Patch - OBJECTIVE: This trial is an open label extension of […]


University Of Phoenix Online Nursing Degrees
  by twi321


Rotigotine Skin Patch May Ease Restless Legs Symptoms
  by Theresa Tamkins
FRIDAY, May 30 (HealthDay News) -- Skin patches that contain the drug rotigotine help relieve restless legs syndrome (RLS), according to a German study. Dopaminergic drugs -- which stimulate […]


News about Neupro Patch - HO, HO, HO!
  by bibmomma
I'm always amazed at the speed in which our Food and Drug Administration draws conclusions about our drugs.ツツ In today's news we find out that the Neupro patch […]


UCB Brings Neupro (R) Back to ALL Patients in Europe
  by bibmomma
UCB announced that Neuproツョ (rotigotine transdermal patch) can now be prescribed to all patients with idiopathic Parkinson's disease in Europe and is newly available for the symptomatic treatment […]


Transdermal Patches and MRIs
  by Laura
Have you heard about transdermal patches and MRIs? It is said that many of these patches have Aluminum in them that help pull the medicationツ into the skin. […]


K2 Pedia! | Study Showed The Clinically Significan …
  by k2pedia
K2 Pedia! | Study Showed The Clinically Significant Therapeutic Benefit Of Neuproテつョ (Rotigotine Transdermal System) In The Treatment Of Restless Legs Syndrome | System, Transdermal, Restless, Legs, Syndrome, […]



Other reviews about Rotigotine Transdermal System on web:

Rotigotine Transdermal Systems Patch. 30 August 2010. Products Affected - Description. Rotigotine transdermal systems (Neupro), UCB 2 mg/24 hours, package of 7 (NDC 00091-6486-21) Bulletin


Evidence of Neuproテδづつョ (Rotigotine Transdermal System) improving motor as well as non-motor symptoms of Parkinson's disease was presented at the 62nd American Academy of Neurology ... Neupro (R) (Rotigotine Transdermal System) Improved Both Motor And ...


Rotigotine transdermal patches are used to treat the signs and symptoms of Parkinson's disease (PD; a disorder of the nervous system that causes difficulties with movement, muscle ... Rotigotine Transdermal: MedlinePlus Drug Information


Section Contents Menu. MedWatch The FDA Safety Information and Adverse Event Reporting Program; Safety Information; Safety Alerts for Human Medical Products Neupro (rotigotine transdermal system)


BRUSSELS, June 18 /PRNewswire-FirstCall/ -- The first data to show that Neuproテδづつョ (rotigotine transdermal system) significantly improved wellbeing and daily activities that are ... Neuproテδづつョ (Rotigotine Transdermal System) Significantly Improved ...


The first patch for Parkinson's disease has recently been approved by the USFDA: Neuproテδづつョ (rotigotine transdermal system) . A Straightfromthedoc: Neuproテδづつョ (rotigotine transdermal system ...


For more information: Contact Andrea Levin 770-970-8352 (phone) andrea.levin@ucb-group.com Rotigotine Transdermal System Shows Significant Symptom Reduction and Tolerability in Patients ... Rotigotine Transdermal System Shows Significant Symptom Reduction ...


Rotigotine transdermal patches are used to treat the signs and symptoms of Parkinsons disease PD a disorder of the nervous system that causes difficulties with movement, muscle ... Rotigotine Transdermal | LIVESTRONG.COM


Neuproテδづつョ (rotigotine transdermal system) Showed Significant Benefit on Early Morning Motor Control, Sleep and Nocturnal Symptoms in Patients With Parkinson's Disease. Neuproテδづつョ (rotigotine transdermal system) Showed Significant ...


The first data to show that Neuproテδづつョ (rotigotine transdermal system) significantly improved wellbeing and daily activities that are often impaired by pain related to Restless Legs ... Neuproテδづつョ (Rotigotine Transdermal System) Significantly Improved ...





Featured Reviews

Reviews Desferal

Desferal Drug Description Desferal® (deferoxamine mesylate) for Injection USP, Vials DRUG DESCRIPTION What are the possible side effects of deferoxamine (Desferal)? Get emergency medical help if you have any of these signs...
Read More  |  Review This
Reviews Meloxicam

Mobic Drug Description Mobic® (meloxicam) Tablets Mobic® (meloxicam) Oral Suspension WARNING RISK OF SERIOUS CARDIOVASCULAR and GASTROINTESTINAL EVENTS Cardiovascular Risk Nonsteroidal anti-inflammatory drugs (NSAIDs)...
Read More  |  Review This
Reviews Clonidine

Catapres-TTS Drug Description Catapres-TTS (clonidine) Catapres-TTS -1 Catapres-TTS -2 Catapres-TTS -3 Transdermal Therapeutic System Programmed delivery in vivo of 0.1, 0.2, or 0.3 mg clonidine per day, for one week. DRUG...
Read More  |  Review This
Reviews Ancobon

Ancobon Drug Description ANCOBON® (flucytosine) Capsules WARNING Use with extreme caution in patients with impaired renal function. Close monitoring of hematologic, renal and hepatic status of all patients is essential. These...
Read More  |  Review This
Reviews Pregnyl

Pregnyl Drug Description PREGNYL® (chorionic gonadotropin) for Injection, USP DRUG DESCRIPTION What are the possible side effects of HCG (Novarel, Ovidrel, Pregnyl)? Stop using HCG and get emergency medical help if you have...
Read More  |  Review This
Recent News
59sec - the BEST lead management system around!
We tested 59sec - THE lead management system and we love it. 59sec helps small and medium companies to answer leads in maximum 59 seconds. Why...
MOVEorPAY - our favorite facebook app
We do love MOVEorPAY motivational facebook app, because it is very cool and useful. It makes you finish stuff that you know are good for you, but from various reasons, you never do...
ReviewsAZ is almost ready to be officially launched
yes, we have just a few loose ends to tie and we are ready to go :) meanwhile, I am putting some reviews on the site, so people will not get an empty site at the launch....